Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Epizyme Inc (EPZM)

Epizyme Inc (EPZM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,398,684
  • Shares Outstanding, K 101,061
  • Annual Sales, $ 23,800 K
  • Annual Income, $ -170,300 K
  • 60-Month Beta 2.11
  • Price/Sales 59.49
  • Price/Cash Flow N/A
  • Price/Book 4.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.56
  • Number of Estimates 7
  • High Estimate -0.53
  • Low Estimate -0.63
  • Prior Year -0.53
  • Growth Rate Est. (year over year) -5.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.51 +4.74%
on 08/03/20
16.68 -15.17%
on 07/07/20
-1.67 (-10.56%)
since 07/02/20
3-Month
13.51 +4.74%
on 08/03/20
22.00 -35.68%
on 06/18/20
-1.60 (-10.16%)
since 05/01/20
52-Week
9.73 +45.43%
on 10/09/19
27.82 -49.14%
on 01/21/20
+1.95 (+15.98%)
since 08/02/19

Most Recent Stories

More News
Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual Conference

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference...

EPZM : 14.33 (+3.54%)
Watch for Epizyme Inc to Potentially Rebound After Falling 1.10% Yesterday

Epizyme Inc (NASDAQ:EPZM) traded in a range yesterday that spanned from a low of $14.57 to a high of $15.08. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $14.75...

EPZM : 14.33 (+3.54%)
After Yesterday's Decline of 1.38%, Epizyme Inc Offers Investors Better Value

Epizyme Inc (NASDAQ:EPZM) traded in a range yesterday that spanned from a low of $14.95 to a high of $15.21. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $15.01...

EPZM : 14.33 (+3.54%)
Watch for Epizyme Inc to Potentially Rebound After Falling 9.51% Yesterday

Epizyme Inc (NASDAQ:EPZM) traded in a range yesterday that spanned from a low of $17.91 to a high of $19.92. Yesterday, the shares fell 9.5%, which took the trading range below the 3-day low of $18.03...

EPZM : 14.33 (+3.54%)
Roche receives FDA approval for cobas EZH2 Mutation Test as a companion diagnostic for patients with follicular lymphoma

, /PRNewswire/ -- Roche (SIX: RO, ROG;OTCQX: RHHBF) today announced U.S. Food and Drug Administration (FDA) approval of the cobas EZH2 Mutation Test as a companion diagnostic for TAZVERIK(tazemetostat),...

EPZM : 14.33 (+3.54%)
Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma

The FDA grants approval to Epizyme's (EPZM) sNDA for lead drug,Tazverik, for two distinct follicular lymphoma indications.

RHHBY : 44.0500 (+2.20%)
GSK : 41.47 (+2.85%)
EPZM : 14.33 (+3.54%)
AKCA : 11.15 (+2.86%)
Are Options Traders Betting on a Big Move in Epizyme (EPZM) Stock?

Investors need to pay close attention to Epizyme (EPZM) stock based on the movements in the options market lately.

EPZM : 14.33 (+3.54%)
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK(TM) (tazemetostat) for Relapsed/Refractory Follicular Lymphoma

--Commercial Organization Fully Prepared to Support Successful Launch in Follicular Lymphoma

EPZM : 14.33 (+3.54%)
Epizyme Inc Up 0.1% Since SmarTrend Uptrend Call (EPZM)

SmarTrend identified an Uptrend for Epizyme Inc (NASDAQ:EPZM) on April 20th, 2020 at $18.28. In approximately 2 months, Epizyme Inc has returned 0.14% as of today's recent price of $18.30.

EPZM : 14.33 (+3.54%)
Epizyme (EPZM) Down 4.4% Since Last Earnings Report: Can It Rebound?

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EPZM : 14.33 (+3.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade EPZM with:

Business Summary

Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 14.25
1st Resistance Point 14.04
Last Price 14.33
1st Support Level 13.61
2nd Support Level 13.39

See More

52-Week High 27.82
Fibonacci 61.8% 20.91
Fibonacci 50% 18.77
Fibonacci 38.2% 16.64
Last Price 14.33
52-Week Low 9.73

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar